These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 9213916

  • 1. [Liver injury under tuberculostatic treatment].
    Fattinger K, Braunschweig S, Reichen J, Meier-Abt PJ, Krähenbühl S.
    Praxis (Bern 1994); 1997 Apr 09; 86(15):626-9. PubMed ID: 9213916
    [Abstract] [Full Text] [Related]

  • 2. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF, de Oliveira e Silva A, Baldi J, de Souza TN, Rizzo PM.
    Arq Gastroenterol; 1996 Apr 09; 33(4):194-200. PubMed ID: 9302332
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
    Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR, Velayati AA.
    Eur J Gastroenterol Hepatol; 2010 Oct 09; 22(10):1235-8. PubMed ID: 20461008
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [-Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-].
    Olivier C, Radal M, Mazaud S, Jonville-Béra AP, Martel C, Autret E.
    Arch Pediatr; 1998 Mar 09; 5(3):289-90. PubMed ID: 10327997
    [Abstract] [Full Text] [Related]

  • 12. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS, Talarmin F, Sane M, Eladari D, Klotz F.
    Dakar Med; 1995 Mar 09; 40(2):129-31. PubMed ID: 9827070
    [Abstract] [Full Text] [Related]

  • 13. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
    McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, Navin TR.
    Clin Infect Dis; 2005 Oct 15; 41(8):1125-33. PubMed ID: 16163632
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
    Vu D, Macdonald L.
    CMAJ; 2001 Oct 02; 165(7):942-3, 946-7. PubMed ID: 11599338
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
    Ohkawa K, Hashiguchi M, Ohno K, Kiuchi C, Takahashi S, Kondo S, Echizen H, Ogata H.
    Clin Pharmacol Ther; 2002 Aug 02; 72(2):220-6. PubMed ID: 12189369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.